Dilon Technologies

Established in 1997 and headquartered in Newport News, Virginia, Dilon Technologies, Inc. operates as a privately held medical device manufacturer with a focus on enhancing patient outcomes, particularly in the realm of women's healthcare and biosurgery. The company provides a portfolio of medical technologies to healthcare providers globally, with a presence in over 76 countries. Dilon's business model centers on the development, manufacturing, and sale of its devices, supported by strategic acquisitions and distribution agreements to expand its product offerings and market reach.

The company's product line addresses critical needs in surgical oncology and hemostasis. A key offering is the MarginProbe system, acquired from Dune Medical, which provides real-time margin assessment during breast cancer surgery to reduce the need for repeat operations. Clinical studies have demonstrated that MarginProbe can lower re-excision rates by 25% to 80%. Another cornerstone product is the Navigator Gamma Probe system, a globally recognized tool for radio-guided lymphatic mapping and tumor localization in surgical procedures. The portfolio is further diversified with the HEMOBLAST Bellows, an FDA-approved powdered surgical hemostat for controlling bleeding in various surgeries, and the TrueView Specimen Radiography System for identifying tumor lesions in tissue samples. Dilon has also expanded into airway management through the acquisition and launch of the CoPilot VL+ video laryngoscope.

Dilon Technologies serves hospitals and healthcare providers, enabling surgeons and clinicians to improve care quality. The company's growth strategy is fueled by a combination of organic product development and strategic acquisitions, such as the purchase of the Navigator gamma probe business from RMD Instruments and assets from Dunemedical. This has been supported by significant financial backing, including a $9 million growth capital investment from JGB Management in mid-2025 to scale operations and support continued revenue growth. The company is led by CEO George Makhoul.

Keywords: medical devices, biosurgery, breast cancer treatment, surgical oncology, margin assessment, lumpectomy, hemostatic agent, gamma probe, lymphatic mapping, tumor localization, video laryngoscope, specimen radiography, surgical solutions, medical technology, diagnostic equipment, women's healthcare, intraoperative tools, cancer detection, surgical hemostasis, radio-guided surgery